Beam Therapeutics annual ebitda margin
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics EBITDA Margin Growth & History (BEAM)
Beam Therapeutics's ebitda margin was −258.62% for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −258.62% | +361.12 pp |
| 2024 | 2024-12-31 | −619.73% | −578.31 pp |
| 2023 | 2023-12-31 | −41.43% | +490.96 pp |
| 2022 | 2022-12-31 | −532.39% | +210.25 pp |
| 2021 | 2021-12-31 | −742.64% | +532694.86 pp |
| 2020 | 2020-12-31 | −533,437.50% | −135376.39 pp |
| 2019 | 2019-12-31 | −398,061.11% | — |
Beam Therapeutics quarterly ebitda margin
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −24,723.06% | −23369.26 pp |
| Q1 2026 | 2026-03-31 | −320.15% | +1202.71 pp |
| Q4 2025 | 2025-12-31 | −10.32% | +304.29 pp |
| Q3 2025 | 2025-09-30 | −1,250.27% | −542.24 pp |
| Q2 2025 | 2025-06-30 | −1,353.80% | −510.12 pp |
| Q1 2025 | 2025-03-31 | −1,522.86% | −190.87 pp |
| Q4 2024 | 2024-12-31 | −314.61% | −358.32 pp |
| Q3 2024 | 2024-09-30 | −708.03% | −108.49 pp |
| Q2 2024 | 2024-06-30 | −843.69% | −359.83 pp |
| Q1 2024 | 2024-03-31 | −1,332.00% | −942.54 pp |
| Q4 2023 | 2023-12-31 | 43.71% | +468.13 pp |
| Q3 2023 | 2023-09-30 | −599.55% | −43.63 pp |
| Q2 2023 | 2023-06-30 | −483.85% | −12.15 pp |
| Q1 2023 | 2023-03-31 | −389.46% | +475.26 pp |
| Q4 2022 | 2022-12-31 | −424.42% | −305.27 pp |
| Q3 2022 | 2022-09-30 | −555.92% | +8341.06 pp |
| Q2 2022 | 2022-06-30 | −471.70% | +954611.63 pp |
| Q1 2022 | 2022-03-31 | −864.72% | +3315385.28 pp |
| Q4 2021 | 2021-12-31 | −119.15% | +658664.18 pp |
| Q3 2021 | 2021-09-30 | −8,896.99% | +592819.68 pp |
| Q2 2021 | 2021-06-30 | −955,083.33% | −536083.33 pp |
| Q1 2021 | 2021-03-31 | −3,316,250.00% | −2862000.00 pp |
| Q4 2020 | 2020-12-31 | −658,783.33% | — |
| Q3 2020 | 2020-09-30 | −601,716.67% | −316450.00 pp |
| Q2 2020 | 2020-06-30 | −419,000.00% | −139116.67 pp |
| Q1 2020 | 2020-03-31 | −454,250.00% | — |
| Q3 2019 | 2019-09-30 | −285,266.67% | — |
| Q2 2019 | 2019-06-30 | −279,883.33% | — |
Beam Therapeutics ebitda margin trends
Over the last five fiscal years, Beam Therapeutics's ebitda margin increased from −533,437.50% to −258.62%, a change of +533178.88 percentage points. The latest reported quarter, Q2 2026, shows −24,723.06%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...